论文部分内容阅读
目的:探讨血脂康对急性心肌梗死(AMI)伴高脂血症患者的调脂作用。方法:36例AMI伴高脂血症患者服药前及服药后4、8周测定血脂。结果:治疗后4、8周,血清总胆固醇(TC)下降16.5％、19.6％,甘油三脂(TG)下降25.9％、28.8％,高密度脂蛋白(HDL—C)升高25％、27.1％,低密度脂蛋白(LDL—C)下降25.5％、29.8％,与治疗前相比,差异有显著性,未见明显毒副作用。结论:血脂康治疗AMI伴高脂血症安全有效。
Objective: To investigate the effect of Xuezhikang on lipid-lowering in patients with acute myocardial infarction (AMI) and hyperlipidemia. Methods: Thirty-six patients with AMI and hyperlipidemia were given lipids before taking the drug and at 4 and 8 weeks after taking the drug. Results: At 4 weeks and 8 weeks after treatment, serum total cholesterol (TC) decreased by 16.5% and 19.6%, TG decreased by 25.9% and 28.8%, HDL-C increased by 25% and 27.1 %, Low density lipoprotein (LDL-C) decreased by 25.5%, 29.8%, compared with before treatment, the difference was significant, no obvious side effects. Conclusion: Xuezhikang safe and effective treatment of AMI with hyperlipidemia.